Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Capital Expenditures (2016 - 2025)

Ironwood Pharmaceuticals' Capital Expenditures history spans 16 years, with the latest figure at -$1000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures changed N/A year-over-year to -$1000.0; the TTM value through Dec 2025 reached $34000.0, down 76.06%, while the annual FY2025 figure was $34000.0, 76.06% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$1000.0 at Ironwood Pharmaceuticals, down from $2000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $211000.0 in Q4 2023 and bottomed at -$27000.0 in Q4 2022.
  • The 5-year median for Capital Expenditures is $31000.0 (2025), against an average of $47533.3.
  • The largest annual shift saw Capital Expenditures crashed 121.09% in 2022 before it soared 881.48% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $128000.0 in 2021, then plummeted by 121.09% to -$27000.0 in 2022, then skyrocketed by 881.48% to $211000.0 in 2023, then crashed by 92.42% to $16000.0 in 2024, then crashed by 106.25% to -$1000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Capital Expenditures are -$1000.0 (Q4 2025), $2000.0 (Q3 2025), and $2000.0 (Q2 2025).